IFx-Hu2.0 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: pAc/emm55

Filter by location:

Los Angeles, California1 trial

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

USC Norris Comprehensive Cancer Center

Phase 2/3

Tampa, Florida1 trial

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.